Navigation Links
Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan
Date:3/11/2010

airman and Chief Executive of Azur Pharma, stated "We are pleased to add PRIALT, an important therapeutic for the management of severe chronic pain, to our portfolio. We look forward to welcoming the PRIALT team to our organisation and to their continued support for this product. We believe PRIALT will grow with continued investment in the brand. The patents covering PRIALT run through December 2016. Our business will have 170 employees at closing and had revenues of approximately $100 million for 2009. We expect to add other products and development projects to both our CNS and Women's Health businesses during the course of 2010 and look forward to the continued growth of our business."

The acquisition is expected to close in the second quarter of 2010. Financial terms are not disclosed. Azur will utilise its existing cash resources to finance the transaction. The acquisition will be EBITDA positive from Closing.

About Azur Pharma

Azur is a privately held pharmaceutical company dedicated to enhancing patients' lives by developing and marketing pharmaceutical products in specialist therapeutic areas. Azur's strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development and approved pharmaceutical products. (Website:

Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the hiring ... of Managed Care. In this role, Damm will build ... nation’s leading specialty pharmacies. , Damm, who is based ... pharmacy and biotech experience to his new position with ... and Pfizer. Prior to working in Healthcare Damm served ...
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... 2015 The next implants made from ... CE mark (European) approval. The CE mark is necessary ... (EFTA) and the European Union. Following the Class IIb ... to implants supplied by the Turkey-based company Osimplant for ... Osimplant's Cervical Expandable Bladed HA PEEK Cage line of ...
(Date:3/4/2015)... The UPMC Center for Health Security today announced the ... in Biosecurity Initiative (ELBI). As part of our commitment ... UPMC has selected 28 US and international emerging leaders ... biological science, medicine, policy, the military, think tanks and ... and support of the Defense Threat Reduction Agency in ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3
... ROCKVILLE, Md., Sept. 2 Human Genome,Sciences, Inc. ... presentation at the,2008 Thomas Weisel Partners Annual Healthcare ... http://www.hgsi.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ... senior management team will present,a corporate overview on ...
... NeurogesX, Inc.,(Nasdaq: NGSX ), a biopharmaceutical ... therapies, announced today that,Anthony DiTonno, President and Chief ... Stanley Global Healthcare Unplugged Conference in New,York City ... Stephen Ghiglieri,Chief Financial Officer, will be available to ...
... patents; Purdue licenses ... oxycodone strengths, STAMFORD, Conn., Sept. 2 Purdue ... Missouri have,agreed to end the OxyContin(R) (oxycodone HCl controlled-release) ... District,Court for the Southern District of New York., ...
Cached Biology Technology:NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 2NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference 3Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc. 2
(Date:2/5/2015)... Calif. , Jan. 30, 2015  It is ... great power and potential for genomic science as a ... in disease prevention and treatment.  I was honored to ... new, government-funded precision medicine program. Since ... the science of genomics—from the first sequenced genome of ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ... A Global Market Overview" report to their offering. ... to ensure that an individual is who she/he is claiming ... use of a person,s unique physical characteristics, such as fingerprint, ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... and smoke forecasting models are useful tools to help ... in areas at risk from forest fire smoke, according ... Brauer shares his insight into the health impacts ... them today at the American Association for the Advancement ...
... This press release is available in French . ... are lots of new ideas out there for giving you extra ... good ideas may never make it to market. Researchers ... a way to enrich milk with docosahexaeonic acid (DHA)an essential nutrient ...
... An international team from the Nippon Foundation-University of British ... of life in the world,s oceans, allowing scientists and ... the state of life in the oceans of ... factors impacting our oceans climate change, human activity ...
Cached Biology News:As climate change increases forest fires, smoke forecasting could help protect public health 2Window into world's future oceans unveiled by NF-UBC Nereus team 2Window into world's future oceans unveiled by NF-UBC Nereus team 3
... Application: The greater incorporation of Br-dUTP results ... when detected using a fluorescein-labeled anti-BrdU antibody. ... in the kit to counterstain the total ... Br-dUTP, resulting in improved detection than found ...
... For transient, cytoplasmic expression of an ... of interest or selection marker from bicistronic ... into MCS1 and MCS2 for transcription of ... This vector is useful for protein-protein interaction ...
...
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
Biology Products: